How to buy Invitrocue (IVQ) shares

Learn how to easily invest in Invitrocue shares.

Invitrocue Limited

We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!

Invitrocue Limited is a biotechnology business based in Australia. Invitrocue shares (IVQ) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian Dollars. Invitrocue has a market cap (total outstanding shares value) of $34.7 million. If you're looking to buy shares, check out the steps below.

How to buy shares in Invitrocue

  1. Compare share trading platforms. To buy shares listed in Australia, you'll need to sign up to a broker with access to the Australian Securities Exchange (ASX). Our table below can help you choose.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, PayPal or debit card.
  3. Search for Invitrocue . Find the share by name or ticker symbol: IVQ. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Invitrocue reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At today's price, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs.
  6. Check in on your investment. Congratulations, you own a part of Invitrocue . Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Invitrocue stock price (ASX:IVQ)

Use our graph to track the performance of IVQ stocks over time.

Invitrocue shares at a glance

Information last updated 2021-04-12.
52-week range$0.06 - $0.06
50-day moving average $0.06
200-day moving average $0.06
Target price$0.47
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.007

Compare share trading platforms

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.
Name Product Standard brokerage fee Inactivity fee Markets
IG Share Trading
Finder Award
IG Share Trading
AUD $8 or 0.1%
$50 per quarter if you make fewer than three trades in that period
ASX shares, Global shares
$0 brokerage for US and global shares plus get an active trader discount of $5 commission on Australian shares.
Enjoy some of the lowest brokerage fees on the market when trading Australian shares, international shares, plus get access to 24-hour customer support.
Superhero share trading
AUD $5
ASX shares, US shares, ETFs
Australia’s lowest-cost broker for ASX shares and ETFs.
Pay zero brokerage on US stocks and all ETFs and just $5 (flat fee) to trade Australian shares from your mobile or desktop.
CMC Markets Stockbroking
AUD $11 or 0.1%
ASX shares, Global shares, mFunds, ETFs
$0 brokerage on global shares including US, UK and Japan markets.
Trade up to 9,000 products, including shares, ETFs and managed funds, plus access up to 15 major global and Australian stock exchanges.
Bell Direct Share Trading
Finder AwardExclusive
Bell Direct Share Trading
AUD $15
ASX shares, mFunds, ETFs
Bell Direct offers a one-second placement guarantee on market-to-limit ASX orders or your trade is free, plus enjoy extensive free research reports from top financial experts.
Saxo Capital Markets (Classic account)
AUD $6.99
ASX shares, Global shares, Forex, CFDs, Margin trading, Options trading, ETFs
Acess 19,000+ stocks on 37 exchanges worldwide
Low fees for Australian and global share trading, no inactivity fees, low currency conversion fee and optimised for mobile.

Compare up to 4 providers

Is it a good time to buy Invitrocue stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Invitrocue financials

Gross profit TTM $252,858
Return on assets TTM -167.33%
Return on equity TTM -1214.48%
Profit margin 0%
Book value 0.003
Market capitalisation $34.7 million

TTM: trailing 12 months

Invitrocue share dividends

We're not expecting Invitrocue to pay a dividend over the next 12 months.

Have Invitrocue 's shares ever split?

Invitrocue 's shares were split on a 1:52 basis on 19 May 2015. So if you had owned 52 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Invitrocue shares – just the quantity. However, indirectly, the new 5100% higher share price could have impacted the market appetite for Invitrocue shares which in turn could have impacted Invitrocue 's share price.

Invitrocue share price volatility

Over the last 12 months, Invitrocue 's shares have ranged in value from as little as $0.06 up to $0.06. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Invitrocue 's is 0.3467. This would suggest that Invitrocue 's shares are less volatile than average (for this exchange).

Invitrocue overview

Invitrocue Limited engages in the research and experimental development on biotechnology, life, and medical science primarily in Singapore, Australia, China, Hong Kong, and Germany. The company develops Onco Patient-Derived Organoid (PDO) test, a personalized cancer treatment for cancer patients; and 3D CelluSponge series, a 3D in-vitro platform technology for various applications, including 3D cell culture, hepatocyte culture, in-vitro drug metabolism and pharmacokinetics assays and toxicology, stem cell differentiation, PDO, and pathogen infection and detection. It also provides respiratory disease, and customized assays and disease modelling services. Invitrocue Limited was founded in 2012 and is headquartered in Singapore.

Invitrocue in the news

There are no recent company news

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs comes with a higher risk of losing money rapidly due to leverage. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder only provides general advice and factual information, so consider your own circumstances, or seek advice before you decide to act on our content. By submitting a question, you're accepting our Terms of Use, Disclaimer & Privacy Policy and Privacy & Cookies Policy.
Go to site
Not sure what platform to go with?
Take this quick quiz to find the right share trading platform